Page 13 - Access Pathway News Today

/PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with...

Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products.Lead programme, LEU011 has completed

- Revenues of $1.11 Billion in 2022, GAAP Loss per Share of $0.97 and Diluted Non-GAAP Earnings per Share of $0.34 - - Achieved LYBALVI® Net Sales of $96.0 Million in First Full Year

Designation Aims to Accelerate Time to Market Toronto, Ontario--(Newsfile Corp. - February 7, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company

Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema - read this article along with other careers information, tips and advice on BioSpace

We have previously noted that 2023 may be a blockbuster year for European biotech deal making. A recent article in the Financial Times examines the…

Aman Khera and Dr Christine Moore of Worldwide Clinical Trials share how regulatory agencies are supporting psychedelic research.

Canadian and US developers of psychedelic medicines for mental health conditions have signed with a CMO to trial their drugs in the UK.

Investegate announcements from COMPASS Pathways, COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

/PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies long-term...